LY2090314 is a small molecule inhibitor of glycogen synthase kinase-3 (GSK-3), primarily investigated for its potential in oncology. It targets the Wnt/β-catenin signaling pathway, which is frequently dysregulated in various cancers, including solid tumors and hematologic malignancies. By potently inhibiting GSK-3, LY2090314 disrupts cell proliferation and survival signals, potentially suppressing tumor growth and sensitizing cancer cells to other therapies. It has been evaluated in clinical trials, particularly in combination regimens for advanced cancers. Preclinical studies also suggest roles in modulating cell differentiation and fate, positioning it as a candidate for regenerative medicine. While GSK-3 inhibition has broader implications in diseases like Alzheimer's and diabetes, LY2090314's development has focused mainly on anticancer applications. Further research is required to confirm its safety and efficacy.